LAKE FOREST, Ill., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced...
-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval...
LAKE FOREST, Ill., July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before...
LAKE FOREST, Ill., July 06, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced that effective July 3, 2018, the Company granted ten newly-hired employees a total of 512,439...
LAKE FOREST, Ill., June 07, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced that the Company will grant Phillip B. Donenberg, the Company’s new Chief Financial Officer and Senior...
LAKE FOREST, Ill., June 05, 2018 (GLOBE NEWSWIRE) -- Lake Forest, Illinois, June 5, 2018 - Depomed, Inc. (NASDAQ:DEPO) today announced that it has appointed Phillip B. Donenberg as Chief...
- Company Confirms Previous 2018 Guidance for Neurology Franchise Net Sales and Non-GAAP Adjusted EBITDA - - Amends Existing Agreement for CAMBIA Line Extension – - Announces New Co-Promotion...
LAKE FOREST, Ill., May 07, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference...
LAKE FOREST, Ill., May 03, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first-quarter 2018 financial results on Thursday, May 10, 2018, before the...
NEWARK, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced the appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales